[Articles] Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden

In this large Scandinavian cohort, use of liraglutide, as compared with use of DPP-4 inhibitors, was associated with significantly reduced risk of major cardiovascular events. Patients with history of cardiovascular disease seemed to derive the largest benefit from treatment with liraglutide. These data provide support for the cardiovascular effectiveness of liraglutide in routine clinical practice.

Bekijk het originele bericht